Literature DB >> 11704049

The role of leptin in choroidal neovascularization.

J Z Cui1, D Hornan, M J Potter, M D Greve, B J Hinz, A Samad, J A Matsubara.   

Abstract

PURPOSE: The purpose of this study was to investigate the role of leptin in choroidal neovascularization.
METHODS: We examined the localization of leptin by immunohistochemistry in nine choroidal neovascular membranes surgically excised from patients with age-related macular degeneration, idiopathic choroidal neovascularization, and ocular histoplasmosis. Controls included omission of primary antibody, use of an irrelevant primary antibody and leptin staining of posterior segment of four normal donor eyes.
RESULTS: Leptin was present in eight membranes and appeared vesicular, within the cytoplasm. The more vascular membranes and those consisting of a larger number of retinal pigment epithelium cells were associated with greater leptin staining. Leptin was not seen in the posterior segment of the four normal eyes.
CONCLUSION: We suggest that leptin plays an active role in choroidal neovascularization, although further experiments are necessary to establish a causal relationship.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11704049     DOI: 10.1016/s0002-9394(01)01105-9

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  3 in total

Review 1.  Is there any connection between choroidal thickness and obesity?

Authors:  Farshad Askarizadeh; Mohsen Heirani; Masoud Khorrami-Nejad; Foroozan Narooie-Noori; Mehdi Khabazkhoob; Alireza Ostadrahimi
Journal:  Ther Adv Ophthalmol       Date:  2022-06-30

2.  Differential expression of angioregulatory factors in normal and CNV-derived human retinal pigment epithelium.

Authors:  Gottfried Martin; Günther Schlunck; Lutz L Hansen; Hansjürgen T Agostini
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2004-01-14       Impact factor: 3.117

3.  Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment.

Authors:  Pear Pongsachareonnont; Michael Ying Kit Mak; Cameron Paul Hurst; Wai-Ching Lam
Journal:  Clin Ophthalmol       Date:  2018-09-26
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.